Paraneoplastic syndromes in neuro-ophthalmology

Journal of Neuro-Ophthalmology

Volumn 35, Issue 3, 2015, Pages 306-314

  Gordon, Lynn K ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; STEROID;

AUTOIMMUNE DISEASE; AUTOIMMUNE PARANEOPLASTIC RETINOPATHY; EATON LAMBERT SYNDROME; EVALUATION AND FOLLOW UP; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROOPHTHALMOLOGY; OCULAR PARANEOPLASTIC SYNDROME; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC OPTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; RETINOPATHY; REVIEW; STEROID THERAPY; VISUAL SYSTEM; NEUROLOGY; OPHTHALMOLOGY; PARANEOPLASTIC SYNDROMES;

HUMANS; NEUROLOGY; OPHTHALMOLOGY; PARANEOPLASTIC SYNDROMES;

EID: 84940545656     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0000000000000280     Document Type: Review

References (62)

1. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev. 2009; 8: 410-414.
2. Bataller L, Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol. 2004; 17: 3-8.
3. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003; 48: 12-38.
4. Jacobson DM. Paraneoplastic disorders of neuro-ophthalmologic interest. Curr Opin Ophthalmol. 1996; 7: 30-38.
5. Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol. 2008; 28: 58-68.
6. Ling CP, Pavesio C. Paraneoplastic syndromes associated with visual loss. Curr Opin Ophthalmol. 2003; 14: 426-432.
7. Wray SH, Dalmau J, Chen A, King S, Leigh RJ. Paraneoplastic disorders of eye movements. Ann N Y Acad Sci. 2011; 1233: 279-284.
8. Rosenfeld MR, Titulaer MJ, Dalmau J. Paraneoplastic syndromes and autoimmune encephalitis: five new things. Neurol Clin Pract. 2012; 2: 215-223.
9. Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Surv Ophthalmol. 2013; 58: 430-458.
10. Khan N, Huang JJ, Foster CS. Cancer associated retinopathy (CAR): an autoimmune-mediated paraneoplastic syndrome. Semin Ophthalmol. 2006; 21: 135-141.
11. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol. 2003; 54: 38-50.
12. Braithwaite T, Vugler A, Tufail A. Autoimmune retinopathy. Ophthalmologica. 2012; 228: 131-142.
13. Dobson R, Lawden M. Melanoma associated retinopathy and how to understand the electroretinogram. Pract Neurol. 2011; 11: 234-239.
14. Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-Associated retinopathy. Arch Ophthalmol. 1992; 110: 48-53.
15. Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol. 1997; 17: 77-83.
16. Shildkrot Y, Sobrin L, Gragoudas ES. Cancer-Associated retinopathy: update on pathogenesis and therapy. Semin Ophthalmol. 2011; 26: 321-328.
17. Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, Keltner JL. Cancer-Associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989; 321: 1589-1594.
18. Thirkill CE, Roth AM, Keltner JL. Cancer-Associated retinopathy. Arch Ophthalmol. 1987; 105: 372-375.
19. Volpe NJ, Rizzo JF III. Retinal disease in neuro-ophthalmology: paraneoplastic retinopathy and the big blind spot syndrome. Semin Ophthalmol. 1995; 10: 234-241.
20. Thirkill CE. Cancer-induced, immune-mediated ocular degenerations. Ocul Immunol Inflamm. 2005; 13: 119-131.
21. Lu Y, Jia L, He S, Hurley MC, Leys MJ, Jayasundera T, Heckenlively JR. Melanoma-Associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009; 127: 1572-1580.
22. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-Associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001; 21: 173-187.
23. Sheorajpanday R, Slabbynck H, Van De Sompel W, Galdermans D, Neetens I, De Deyn PP. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP)-5 paraneoplastic optic neuropathy. J Neuroophthalmol. 2006; 26: 168-172.
24. Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol. 2001; 21: 164-167.
25. Slamovits TL, Posner JB, Reidy DL, Thirkill CE, Keltner JL. Pancreatic neuroendocrine paraneoplastic optic neuropathy: confirmation with antibody to optic nerve and hepatic metastasis. J Neuroophthalmol. 2013; 33: 21-25.
26. Hoh ST, Teh M, Chew SJ. Paraneoplastic optic neuropathy in nasopharyngeal carcinoma-report of a case. Singapore Med J. 1991; 32: 170-173.
27. Chao D, Chen WC, Thirkill CE, Lee AG. Paraneoplastic optic neuropathy and retinopathy associated with colon adenocarcinoma. Can J Ophthalmol. 2013; 48: e116-e120.
28. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001; 49: 146-154.
29. Nakano S, Kanamori A, Nakamura M, Mizukawa K, Negi A. Paraneoplastic optic neuropathy associated with cerebellar choroid meningioma. Eye (Lond). 2013; 27: 1220-1221.
30. Kaushik M, Pulido JS, Abreu R, Amselem L, Dispenzieri A. Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Ophthalmology. 2011; 118: 778-782.
31. Lally DR, Moster ML, Foroozan R. Muscle cramping over the diagnosis. Surv Ophthalmol. 2014; 59: 128-131.
32. Jen JC, Lopez I, Baloh RW. Opsoclonus: clinical and immunological features. J Neurol Sci. 2012; 320: 61-65.
33. Hero B, Schleiermacher G. Update on pediatric opsoclonus myoclonus syndrome. Neuropediatrics. 2013; 44: 324-329.
34. Laroumagne S, Elharrar X, Coiffard B, Plojoux J, Dutau H, Breen D, Astoul P. Dancing eye syndrome secondary to opsoclonus-myoclonus syndrome in small-cell lung cancer. Case Rep Med. 2014: 545490.
35. Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, Kumar R, McEvoy KF, McKeon A. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012; 69: 1598-1607.
36. Scarff JR, Iftikhar B, Tatugade A, Choi J, Lippmann S. Opsoclonus myoclonus. Innov Clin Neurosci. 2011; 8: 29-31.
37. Sahu JK, Prasad K. The opsoclonus-myoclonus syndrome. Pract Neurol. 2011; 11: 160-166.
38. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child. 2012; 97: 461-463.
39. Yamaguchi Y, Wada M, Tanji H, Kurokawa K, Kawanami T, Ohtake H, Kato T. Marked improvement in opsoclonus and cerebellar ataxia after the surgical removal of a squamous cell carcinoma of the thymus: a case report. J Neurol Sci. 2013; 325: 156-159.
40. Kruger JM, Yonekawa Y, Skidd P, Cestari DM. Ocular flutter as the presenting sign of lung adenocarcinoma. Digit J Ophthalmol. 2014; 20: 4-6.
41. Dot C, Guigay J, Adamus G. Anti-Alpha-enolase antibodies in cancer-Associated retinopathy with small cell carcinoma of the lung. Am J Ophthalmol. 2005; 139: 746-747.
42. Weleber RG, Watzke RC, Shults WT, Trzupek KM, Heckenlively JR, Egan RA, Adamus G. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005; 139: 780-794.
43. Shiraga S, Adamus G. Mechanism of CAR syndrome: antirecoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9-And caspase 3-dependent pathway. J Neuroimmunol. 2002; 132: 72-82.
44. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev. 2003; 2: 63-68.
45. Shimazaki K, Jirawuthiworavong GV, Heckenlively JR, Gordon LK. Frequency of anti-retinal antibodies in normal human serum. J Neuroophthalmol. 2008; 28: 5-11.
46. Forooghian F, Macdonald IM, Heckenlively JR, Heon E, Gordon LK, Hooks JJ, Detrick B, Nussenblatt RB. The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol. 2008; 146: 489-495.
47. Faez S, Loewenstein J, Sobrin L. Concordance of antiretinal antibody testing results between laboratories in autoimmune retinopathy. JAMA Ophthalmol. 2013; 131: 113-115.
48. Saito M, Saito W, Kanda A, Ohguro H, Ishida S. A case of paraneoplastic optic neuropathy and outer retinitis positive for autoantibodies against collapsin response mediator protein-5, recoverin, and alpha-enolase. BMC Ophthalmol. 2014; 14: 5.
49. Margolin E, Flint A, Trobe JD. High-Titer collapsin responsemediating protein-Associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma. J Neuroophthalmol. 2008; 28: 17-22.
50. Blaes F, Fuhlhuber V, Preissner KT. Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome. Expert Rev Clin Immunol. 2007; 3: 975-982.
51. Kirsten A, Beck S, Fuhlhuber V, Kaps M, Kreutz T, Korfei M, Schmitt S, Preissner KT, Blaes F. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann N Y Acad Sci. 2007; 1110: 256-260.
52. McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology. 2011; 76: 1108-1110.
53. Schoenberger SD, Kim SJ, Lavin P. Paraneoplastic optic neuropathy from cutaneous melanoma detected by positron emission tomographic and computed tomographic scanning. Arch Ophthalmol. 2012; 130: 1223-1225.
54. Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol. 2009; 127: 390-397.
55. Or C, Collins DR, Merkur AB, Wang Y, Chan CC, Forooghian F. Intravenous rituximab for the treatment of cancer-Associated retinopathy. Can J Ophthalmol. 2013; 48: e35-e38.
56. Jaben EA, Pulido JS, Pittock S, Markovic S, Winters JL. The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases. J Clin Apher. 2011; 26: 356-3561.
57. Pulido J, Cross SA, Lennon VA, Pulido J, Swanson D, Muench M, Lachance DH Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond) 2008 22 1191-1193.
58. Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics. 2011; 128: e388-e394.
59. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011; 2: CD003279.
60. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011; 10: 1098-1107.
61. Maddison P. Treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci. 2012; 1275: 78-84.
62. Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013; 33: 10559-10567.